A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus

PHASE2TerminatedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

November 1, 2011

Primary Completion Date

July 30, 2012

Study Completion Date

July 30, 2012

Conditions
Discoid Lupus
Interventions
DRUG

CC-930

DRUG

Placebo

Placebo

Trial Locations (19)

14623

University of Rochester Medical Center, Rochester

20037

Medical Faculty Associates, Washington D.C.

21205

John Hopkins University, Baltimore

29425

Medical University of South Carolina, Charleston

33136

Advanced Pharma, CR, LLC, Miami

University of Miami - Department of Dermatology, Miami

35233

UAB Dermatology, Birmingham

43221

Ohio State Univ Medical Center, Division of Dermatology, Columbus

55455

University of Minnesota-Department of Dermatology, Minneapolis

60077

North Shore University Health System, Skokie

60612

Rush Medical Center, Chicago

62702

SIU School of Medicine, Springfield

70112

Tulane University School of Medicine, New Orleans

75230

Dermatology and Research, Dallas

77030

University of Texas Dermatology, Houston

78215

Sun Research Institute, San Antonio

92697

The Regents of the University of California, Irvine

02118

Boston Cancer Center, Boston

02903

Rhode Island Hospital University Dermatology, Inc., Providence

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT01466725 - A Research Study to Assess if CC-930 is Safe in Treating Subjects With Discoid Lupus Erythematosus | Biotech Hunter | Biotech Hunter